This week, learn about the Center for Discovery and Innovation's research around vaccines and the next generation of rifamycins, as well as results from a Cefiderocol study looking at healthcare-associated Gram-negative bloodstream infections and more.
FDA clearance paves the way for Invivyd to launch 2 phase 3 trials of VYD2311, a monoclonal antibody designed as a safe, convenient, vaccine alternative for COVID-19 prevention.
NIH funds an effort to adapt an electrochemical biosensor for same-visit detection and viral-load quantification at the point of care.
The Phase 3 PRIOH-1 trial demonstrated that pritelivir, a first-in-class helicase-primase inhibitor, achieved statistically superior lesion healing compared to standard therapies, offering a promising new oral treatment option for immunocompromised patients with refractory HSV infections.
Veronique Dartois, PhD, and Thomas Dick, PhD, discuss the multidrug resistance associated with non-TB mycobacteria and their research, which focuses on developing a novel version of this class of antibiotics for these infections.
Initial findings from the phase 1 CLARITY study offer the first direct comparison of the acceptability and tolerability of single-dose cabotegravir and lenacapavir long-acting injections in HIV-negative adults, revealing differences in patient and health care provider preferences.
A UK hepatology review found that one-third of adults with chronic hepatitis B were lost to specialist follow-up—highlighting major gaps in patient retention that threaten progress toward WHO’s 2030 viral hepatitis elimination goals.
A 4-week course of glecaprevir/pibrentasvir achieved sustained virologic response in 84% of patients with early hepatitis C infection in the PURGE-C trial, suggesting potential for shorter, more accessible treatment regimens pending further validation.
George Sakoulas, MD, discusses how ceftaroline serves as an effective stewardship-aligned option for community-acquired pneumonia involving gram-positive organisms, particularly in older and high-risk patients, while noting its limitations in gram-negative and health care–associated infections.
Barry Kreiswirth, PhD, discusses how taking an approach similar to that for streptococcal pneumonia can be applied to a potential Klebsiella vaccine.
John Osiecki, PhD, explains how faster, standardized testing can speed detection and strengthen antimicrobial stewardship.
Cefiderocol is noninferior to standard of care empiric treatment of noscomial Gram-negative bloodstream infections in open-label "Game-Changer" trial.
This week, learn about the Center for Discovery and Innovation's research around antivirals, the hepatitis C bill in Congress, how AI is influencing antimicrobial development, and more.
The Center for Discovery and Innovation’s Barry Kreiswirth, PhD, discusses this emerging challenge that is ongoing in both the community and healthcare settings, especially around resistant urinary tract infections and how this type of resistance can grow exponentially across strain and pathogens.
AI predicted mechanism of action for investigational, narrow spectrum antibiotic against pathogens in Crohn's disease and IBD-related conditions.
David Perlin, PhD, chief scientific officer and executive vice president, the Center for Discovery and Innovation (CDI), talks about his team’s work around developing a diagnostic for Candida auris, and what they are working on in terms of developing antifungals.
The company is advancing R327G, a novel synthetic anti-infective for diabetic foot infections, through a phase 3 clinical trial in Indonesia, marking a major step toward the first new anti-infective class approval in over 40 years.
The Center for Discovery and Innovation’s chief scientific officer David Perlin, PhD, discusses the factors for the growing number of cases and the difficulties in developing such treatments.
Through the bipartisan Cure Hepatitis C Act of 2025, legislation seeks to provide nationwide hepatitis C treatment and strengthen public health infrastructure by expanding testing, treatment, and prevention through a subscription-based model.
The center’s chief scientific officer David Perlin, PhD, provides some insights on the evolution of its antiviral program from its foundation in treating COVID-19 to addressing all pan-coronaviruses.
Your liver silently powers and protects your body every day, but untreated hepatitis infections, excessive alcohol, and poor diet can destroy its vital cells, leading to fatigue, cirrhosis, and liver cancer if not prevented through awareness and care.
The US Department of Agriculture’s Food Safety and Inspection Service (FSIS) provides information on the 2 companies recalls and the products.
William Schaffner, MD, provides more context to the committee’s vaccines recommendations.
Despite modest progress, Staphylococcus aureus bloodstream infections—particularly those caused by MRSA—remain a major cause of morbidity and mortality, underscoring the urgent need for novel, broad-spectrum treatments such as ceftobiprole that can address both resistant and susceptible strains.
This week, there are C diff and hepatitis roundup reports, how COVID-19 has disrupted traditional respiratory virus patterns with summer surges now preceding the typical winter influenza season, a review of a trial comparing dalbavancin with standard intravenous therapy for Staphylococcus aureus, and more.
University of Oregon researchers found that adding a common chemical, chlorate, to standard antibiotics made them up to 10,000 times more effective in lab tests against hard-to-treat bacteria, offering a potential breakthrough for chronic wound care.
Infections caused by NDM-producing carbapenem-resistant Enterobacterales have risen more than 4-fold since 2019, raising alarms about limited treatment options, delayed detection, and heightened risks of transmission and mortality in health care settings. TAXIS Pharmaceuticals Chief Scientific Officer Ajit Parhi, PhD, offers some insights on NDM-CRE, antimicrobial resistance, and an overview of his company’s pipeline.
Recce Pharmaceuticals has begun its study for this indication in Indonesia with its investigational product, RECCE 327 topical gel (R327G).
Stewardship programs that reduce initial use of extended-spectrum antibiotics appear to influence antibiotic choice throughout hospitalization.
Low vaccination rates did not rise sufficiently to attain "herd immunity" after a measles outbreak in a region in which it had been eliminated.
